{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(13)"],"submitter":["Konopleva M"],"pubmed_abstract":["<h4>Purpose</h4>To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia.<h4>Patients and methods</h4>Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax + azacitidine. Enrolled patients were ineligible for intensive therapy due to age ≥75 years and/or comorbidities. Patients on venetoclax + azacitidine received venetoclax 400 mg orally (days 1-28) and azacitidine (75 mg/m2; days 1-7/28-day cycle). FLT3 mutation was analyzed centrally on pretreatment bone marrow aspirates.<h4>Results</h4>In the biomarker evaluable population, "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["2744-2752"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9365380"],"repository":["biostudies-literature"],"pubmed_title":["Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia."],"pmcid":["PMC9365380"],"pubmed_authors":["Miller CL","Pratz KW","Pullarkat V","Recher C","Thirman MJ","Garcia JS","Kantarjian HM","Konopleva M","DiNardo CD","Potluri J","Wei AH","Dail M","Chyla B","Duan Y"],"additional_accession":[]},"is_claimable":false,"name":"Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia.","description":"<h4>Purpose</h4>To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia.<h4>Patients and methods</h4>Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax + azacitidine. Enrolled patients were ineligible for intensive therapy due to age ≥75 years and/or comorbidities. Patients on venetoclax + azacitidine received venetoclax 400 mg orally (days 1-28) and azacitidine (75 mg/m2; days 1-7/28-day cycle). FLT3 mutation was analyzed centrally on pretreatment bone marrow aspirates.<h4>Results</h4>In the biomarker evaluable population, ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2026-05-09T22:15:57.874Z","creation":"2025-04-04T20:22:15.153Z"},"accession":"S-EPMC9365380","cross_references":{"pubmed":["35063965"],"doi":["10.1158/1078-0432.CCR-21-3405"]}}